Liraglutide Improves Both Weight and Menstrual Regularity in Women with PCOS

In a meta-analysis of 7 RCTs (330 women with PCOS), liraglutide significantly improved both metabolic and reproductive outcomes: it increased menstrual frequency (g=1.76), reduced BMI (g=-0.52), improved insulin resistance (HOMA-IR g=-0.52), lowered luteinizing hormone and free androgen index, and modestly increased sex hormone-binding globulin. Adverse events were mainly mild GI symptoms. Ovulation and pregnancy outcomes could not be pooled due to insufficient data from the included trials.

Systematic review and meta-analysis of RCTs comparing liraglutide (alone or combined) to placebo, metformin, or other active treatments in overweight/obese PCOS women. Six databases searched through May 2025. Random-effects model used. Results expressed as Hedges' g or odds ratios with 95% CIs.

PCOS affects 6-12% of reproductive-age women and causes both metabolic problems (insulin resistance, weight gain) and reproductive dysfunction (irregular periods, infertility). This meta-analysis provides the first pooled evidence that liraglutide addresses both dimensions simultaneously — improving insulin sensitivity and weight while also restoring menstrual regularity and improving hormonal balance.

GLP-1 drugs are rapidly expanding beyond diabetes and obesity into adjacent conditions where metabolic dysfunction drives disease. PCOS is a prime example — insulin resistance fuels the hormonal imbalance that causes irregular periods and infertility. This meta-analysis adds to growing evidence that GLP-1 agonists could become a treatment for PCOS, particularly as newer, more potent agents like semaglutide and tirzepatide become available.

Small total sample of only 330 women across 7 trials. High heterogeneity for menstrual frequency outcome. Ovulation and pregnancy rates could not be analyzed due to insufficient reporting. Most studies likely used the 1.8 mg diabetes dose rather than the 3.0 mg weight loss dose. No long-term follow-up data.